MTBVAC - one of the most promising new TB Vaccines with Dr Carlos Martín Montañés Artwork

The TBPod

The TBPod is a podcast for clinicians and policymakers caring for patients with tuberculosis. The podcasts present discussions with expert clinicians, researchers, policymakers and advocates about their work in the field of tuberculosis. Tuberculosis remains one of the leading causes of death worldwide, and is an important contributor to morbidity among migrants arriving in Australia and New Zealand. There are around 1300 reported cases of TB in Australia each year, and a further 300 in New Zealand. Included in these figures are cases of multi-drug resistant (MDR) TB which pose significant barriers to treatment and management of the disease. The Australian government has committed to the global elimination of TB by 2030, but to do so requires the development of innovative new strategies, based on high-quality research, that has national and international reach. These podcasts aim to engage and update those who are interested in the field of tuberculosis through discussions with leaders in the field of tuberculosis.

All Episodes

The TBPod

MTBVAC - one of the most promising new TB Vaccines with Dr Carlos Martín Montañés

May 31, 2024 • Actnet

Today we discuss the MTBVAC with Dr Montañés. MTBVAC is an attenuated vaccine from a human mycobacterial isolate which has just progressed to a phase 3 trial and shown very promising results in the phase 2 study. Dr Montañés has been involved in this project for over a decade and has an incredible insight into the development and promise of this vaccine for global TB epidemiology.

References
Martín, Carlos, et al. "MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG." Vaccine 39.50 (2021): 7277-7285.

Achkar, Jacqueline M. "Prospects and challenges of a new live tuberculosis vaccine." The Lancet Respiratory Medicine 7.9 (2019): 723-725.

Arbues, Ainhoa, et al. "Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials." Vaccine 31.42 (2013): 4867-4873.

Tameris, Michele, et al. "Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial." The lancet Respiratory medicine 7.9 (2019): 757-770.

Spertini, François, et al. "Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial." The lancet Respiratory medicine 3.12 (2015): 953-962.

Gonzalo-Asensio, Jesus, et al. "MTBVAC: attenuating the human pathogen of tuberculosis (TB) toward a promising vaccine against the TB epidemic." Frontiers in immunology 8 (2017): 296893.